<DOC>
	<DOC>NCT01516424</DOC>
	<brief_summary>A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone</brief_summary>
	<brief_title>Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone</brief_title>
	<detailed_description>A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone Trial drugs: - Blonanserin group: Blonanserin tablets+Risperidone mimetic tablets - Risperidone group: Risperidone tablets+Blonanserin mimetic tablets Objectives of Study : To evaluate the efficacy and safety of Blonanserin in treating schizophrenia</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subject met DSMIVTR criteria for a primary diagnosis of schizophrenia Patients are 18≤age≤65 years of age on the day when informed consent is obtained. Subject had a PANSS total score ≥70 and 120≥ at Screening Subject had a score ≥4 on the PANSS at Screening and Baseline. Subjects are willing and able to comply with study protocol including treatment in hospital. Subjects or their legal guardians have signed the written informed consent form. The subject was treatment with other Investigate product within 30 days. Subject had a history of treatment with longacting drug for anti schizophrenia within 56 days. Subject had a history of treatment with clozapine within 28 days. Subject With parkinson disease,etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Blonanserin</keyword>
</DOC>